Eiger BioPharma up after dosing begins in COVID-19 outpatient study

Eiger Biopharmaceuticals

06/07/2021 14:31

** Shares of drug developer  EIGR.O  up 2.6% at $8.65
premarket
    ** Co says first participant dosed in late-stage study of
its experimental drug, Lambda, in outpatients with COVID-19
 urn:newsml:reuters.com:*:nPnCqlkZa
    ** Lambda is administered as a one-time, subcutaneous dose
to outpatients
    ** Main goal of the study is clinical outcome comparing
emergency room visits and/or hospitalization versus placebo
    ** Eiger is also developing Lambda as a standalone therapy
and in combination with other drugs for treatment of hepatitis
delta virus (HDV) infection
    ** EIGR was down ~31% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))